Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes technology to timely reverse the multi-organ complications arising from liver cirrhosis. It was shown to be safe and well tolerated in a Ph1b study with positive efficacy outcomes, and is now ready to start Phase 2a clinical investigations. VS-01 was granted orphan drug designations by the FDA and EMA, which help streamlining its clinical development pathway.
News
Milestones/News
Documents
- Press release Phase 1b
- Press release RPDD
- Press release Board appointment
- Press release Series B
- Press release CMO
- Press release Series A
- Press release Medical Board
Videos and Presentations
Trailer of the company
The product by the founders